February 24, 2009 - BrachySciences, a provider of medical devices for the treatment of early stage prostate cancer, has signed a distribution agreement with IsoRay Inc. to distribute manufacturer of Proxcelan, making BrachySciences the only provider of all three radioactive isotopes used in low dose rate (LDR) prostate brachytherapy.
IsoRay’s Cesium-131 is the only radioactive source available for brachytherapy. BrachySciences has added Cesium-131 source to its distribution portfolio of Advantage Iodine-125 and the TheraSeed Palladium-103 device.
With access to all three isotopes and a diverse brachytherapy product portfolio capable of satisfying any pre-planned or real-time implant technique, BrachySciences has the ability to function as a solitary vendor and complete service provider to hospitals and clinics with LDR implant programs.
For more information: brachysciences.com